One important metric to look for in a stock is an 80 or higher Relative Strength Rating. Ionis Pharmaceuticals now clears that threshold, with a jump from 78 to 82 Wednesday.
Looking For The Best Stocks To Buy And Watch? Start Here
This unique rating tracks technical performance by showing how a stock's price action over the last 52 weeks compares to that of other stocks on the major indexes.
Over 100 years of market history reveals that the market's biggest winners tend to have an RS Rating north of 80 as they begin their biggest price moves.
While the stock is not near a proper buy zone right now, see if it goes on to form and break out of a proper chart pattern.
Ionis Pharmaceuticals posted 0% EPS growth last quarter. Revenue rose 101%.
The company earns the No. 60 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Rigel Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
